Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-061537

EVP, CBO, GC & Secretary sold 137,061 shares at an average $17.53 ($2,402,227)

  • EVP, CBO, GC & Secretary acquired 137,061 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Primiano Christopher Brett · EVP, CBO, GC & Secretary

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2020-12-01 Exercise or conversion : show line 1 in the form +78,124 $10.45 $816,396 82,647 D
2020-12-01 Sale : show line 2 in the form −78,124 $17.66 $1,379,670 4,523 D
2020-12-01 Exercise or conversion : show line 3 in the form +58,937 $10.39 $612,355 63,460 D
2020-12-01 Sale : show line 4 in the form −58,937 $17.35 $1,022,557 4,523 D
Open-market sales · 137,061 sh · avg $17.53 · $2,402,227

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-12-01 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −78,124 $10.45 2028-01-23 78,124 46,876 D
2020-12-01 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −58,937 $10.39 2027-01-19 58,937 16,842 D
Loading xslF345X03/doc4.xml…